Bevirimat: Anti-HIV agent viral maturation inhibitor

Drugs of the Future

Volumn 32, Issue 1, 2007, Pages 7-11

  Wang, Y ^a   Serradell, N ^b  

^a Prous Science ^*  (United States)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; BETULIC ACID; BEVIRIMAT DIMEGLUMINE; GAG PROTEIN; INDINAVIR; NEVIRAPINE; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESEARCH; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

EID: 34247565137     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.01.1064019     Document Type: Article

References (44)

1. Fujioka, T., Kashiwada, Y., Kilkuskie, R.E. et al. Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J Nat Prod 1994, 57(2): 243-7.
2. Kashiwada, Y., Hashimoto, F., Cosentino, L.M., Chen, C.-H., Garrett, P.E., Lee, K.-H. Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. J Med Chem 1996, 39(5): 1016-7.
3. Cosentino, L.M., Fujioka, T., Hu, C.Q. et al. Anti-AIDS agents. 30. Anti-HIV activity of oleanolic acid, pomolic acid, and structurally related triterpenoids. J Nat Prod 1998, 61(9): 1090-5.
4. Hashimoto, F., Kashiwada, Y., Cosentino, L.M., Chen, C.-H., Garrett, P.E., Lee, K.-H. Anti-AIDS agents - XXVII. Synthesis and anti-HIV activity of betulinic acid and dihydrobetulinic acid derivatives. Bioorg Med Chem 1997, 5(12): 2133-43.
5. Cosentino, L.M., Hashimoto, F., Kashiwada, Y., Lee, K.-H., Manak, M. (Biotech Res. Lab.; Univ. North Carolina). Betulinic acid derivs. and uses thereof. EP 1397957, US 5679828, WO 9639033.
6. Murphy, E.L., Collier, A.C., Kalish, L.A. et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001, 135(1): 17-26.
7. Palella, F.J., Delaney, K.M., Moorman, A.C. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl J Med 1998, 338(13): 853-60.
8. Ammassari, A., Murri, R., Pezzotti, P. et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001, 28(5): 445-9.
9. Hubbard, M. Dealing with the obstacles in adhering to highly active antiretroviral therapy. J Assoc Nurses AIDS Care 2006, 17(1): 18-25.
10. Struble, K., Murray, J., Cheng, B., Gegeny, T., Miller, V., Gulick, R. Antiretroviral therapies for treatment-experienced patients: Current status and research challenges. AIDS 2005, 19(8): 747-56.
11. Richman, D.D. HIV chemotherapy. Nature 2001, 410: 991-1001.
12. LaBonte, J., Lebbos, J., Kirkpatrick, P. Enfuvirtide. Nat Rev Drug Discov 2003, 2(5): 345-6.
13. McNicholl, I.R., McNicholl, J.J. On the horizon: Promising investigational antiretroviral agents. Curr Pharm Des 2006, 12(9): 1091-103.
14. Prous Science Disease Briefings: HIV and AIDS (online publication) 2006.
15. Wild, C.T., Li, F., Kilgore, N.R., Martin, D.E., Lee, K., Allaway, G.P. Maturation inhibitors: A new class of HIV-1 therapeutics. Int Chem Congr Pacific Basin Soc (Dec 15-20, Honolulu) 2005, Abst 103.
16. Kilgore, N.R., Reddick, M., Zuiderhof, M. et al. The first-inclass maturation inhibitor, PA-457, is a potent inhibitor of HIV-1 drug-resistant isolates and acts synergistically with approved HIV drugs in vitro. 13th Conf Retroviruses Opportunistic Infect (CROI) (Feb 5-9, Denver) 2006, Abst 509.
17. Li, F., Goila-Gaur, R., Salzwedel, K. et al. PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci USA 2003, 100(23): 13555-60.
18. Kanamoto, T., Kashiwaada, Y., Kanbara, K. et al. Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation. Antimicrob Agents Chemother 2001, 45(4): 1225-30.
19. Martin, D.E. Recent data on PA-457 maturation inhibitor. 14th Int Symp HIV Emerg Infect Dis (ISHEID) (June 21-23, Toulon) 2006, Abst OP 4.5.
20. Zhou, J., Chen, C.H., Aiken, C. The sequence of the CA-SPI junction accounts for the differential sensitivity of HIV-I and SIV to the small molecule maturation inhibitor 3-0-{3′,3′-dimethylsuccinyl}-betulinic acid. Retrovirology 2004, 1: 15.
21. Li, F., Zoumplis, D., Matallana, C. et al. The determinants of activity of the HIV-1 maturation inhibitor PA-457 map to residues flanking the Gag CA-SP1 cleavage site. 12th Conf Retroviruses Opportunistic Infect (Feb 22-25, Boston) 2005, Abst 256.
22. Zhou, J., Yuan, X., Dismuke, D. et al. Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol 2004, 78(2): 922-9.
23. Zhou, J., Huang, L., Hachey, D.L., Chen, C.H., Aiken, C. Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles. J Biol Chem 2005, 280(51): 42149-55.
24. Sakalian, M., McMurtrey, C.P., Deeg, F.J., Maloy, C.W., Li, F., Wild, C.T., Salzwedel, K. 3-O-(3′,3′-Dimethylsuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro. J Virol 2006, 80(12): 5716-22.
25. Lee, K. Recent progress in the discovery and development of plant-derived chemotherapeutic agents. Int Chem Congr Pacific Basin Soc (Dec 15-20, Honolulu) 2005, Abst 1395.
26. Allaway, G.P., Bare, J., Kilgore, N.R., Reddick, M., Martin, D.E., Wild, C.T., Stoddart, C.A. The first-in-class maturation inhibitor, PA-457, is a potent inhibitor of HIV-replication both in vitro and in vivo. 15th Annu Int AIDS Conf (July 11-16, Bangkok) 2004, Abst WePeA5643.
27. Wild, C., Kilgore, N.R., Reddick, M.S. et al. In vitro and in vivo pre-clinical analyses of PA-457, a novel betulinic acid derivative that potently inhibits HIV-1 replication. 14th Int AIDS Conf (July 7-12, Barcelona) 2002, Abst MoPeA3030.
28. Adamson, C., Salzwedel, K., Castillo, A. et al. Viral resistance to PA-457, a novel inhibitor of HIV-1 maturation. 13th Conf Retroviruses Opportunistic Infect (Feb 5-9, Denver) 2006, Abst 156.
29. Salzwedel, K., Goila-Gaur, R., Adamson, C. et al. Selection for and characterization of HIV-1 isolates resistant to the maturation inhibitor PA-457. 13th Int HIV Drug Resist Workshop: Basic Princ Clin Implic (June 8-12, Adeje), 2004, Abst 4.
30. Salzwedel, K., Goila-Gaur, R., Li, F. et al. Selection for and characterization of HIV-1 isolates resistant to the maturation inhibitor PA-457. 15th Int AIDS Conf (July 11-16, Bangkok) 2004, Abst WeOrA1276.
31. Castillo, A., Adamson, C., Doto, J., et al. Genotypic analysis of the Gag CA/SPI cleavage site in patients receiving the maturation inhibitor PA-457. 15th Int HIV Drug Resist Workshop (June 13-17, Sitges) 2006, Abst 32.
32. Wen, Z., Stern, S.T., Martin, D.E., Lee, K.-H., Smith, P.C. Structural characterization of anti-HIV drug candidate PA-457 [3-O-(3′,3′- dimethylsuccinyl)-betulinic acid] and its acyl glucuronides in rat bile and evaluation of in vitro stability in human and animal liver microsomes and plasma. Drug Metab Dispos 2006, 34(9): 1436-42.
33. Martin, D.E., Smith, P., Goila-Gaur, R. et al. Determinants of activity, in vitro metabolism and in vivo disposition of the novel maturation inhibitor PA-457. 11th Conf Retroviruses Opportunistic Infect (CROI) (Feb 8-11, San Francisco) 2004, Abst 545.
34. Martin, D.E., Smith, P., Wild, C.T., Allaway, G.P. In vitro and in vivo disposition of PA-457, a novel inhibitor of HIV-1 maturation. 15th Int AIDS Conf (July 11-16, Bangkok) 2004, Abst WePeA5644.
35. Smith, P.C., Bender, B.C., Wild, C.T., Allaway, G.P., Martin, D.E. Disposition of PA-457, a novel inhibitor of HIV-1 maturation, in rats involves extensive biliary excretion of a glucuronide. Drug Metab Rev 2003, 35(Suppl. 2): Abst 442.
36. Martin, D.E., Ballow, C.H., Blum R., Doto, J., Wild, C.T., Allaway, G.P. The safety, tolerability and pharmacokinetics of PA-457, a first-in-class HIV maturation inhibitor, in healthy volunteers. 7th Int Cong Drug Ther HIV Infect (Nov 14-18, Glasgow) 2004, Abst P312.
37. Martin, D.E., Ballow, C., Doto, J., Blum, R., Wild, C., Allaway, G. The safety, tolerability, and pharmacokinetics of multiple oral doses of PA-457, the first-in-class HIV maturation inhibitor, in healthy volunteers. 12th Conf Retroviruses Opportunistic Infect (Feb 22-25, Boston) 2005, Abst 551.
38. Ogundele, A., Smith, P., Forrest, A., Martin, D. Pharmacokinetic/ pharmacodynamic effects of a novel maturation inhibitor (PA-457) in HIV-infected patients following a single oral dose. 3rd Int AIDS Soc Conf HIV Pathog Treat (July 24-27, Rio de Janeiro) 2005, Abst TuPe3.1B01.
39. Smith, P., Ogundele, A., Forrest, A., Martin, D.E. PKPD modeling & simulation of PA-457 from a single dose viral dynamic study in HIV-infected patients. 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst A-1149.
40. Smith, P., Forrest, A., Beatty, G. et al. Pharmacokinetics/ pharmacodynamics of PA-457 in a 10-day multiple dose monotherapy trial in HIV-infected patients. 13th Conf Retroviruses Opportunistic Infect (CROI) (Feb 5-9, Denver) 2006, Abst 52.
41. Martin, D.E., Alexander, T., Bollinger, J. et al. PA-457, a first-in-class maturation inhibitor, is non-teratogenic in rats an rabbits. 16th Int AIDS Conf (Aug 13-18, Toronto) 2006, Abst CDA0140.
42. Beatty, G., Laleazari, J., Eron, J. et al. Safety and antiviral activity of PA-457, the first-in-class maturation inhibitor, in a 10-day monotherapy study in HIV-1 infected patients. 45th lntersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst H-416d.
43. Martin, D.E., Jacobson, J., Schurmann, D., Osswald, E., Doto, J., Wild, C., Allaway, G. PA-457, the first-in-class maturation inhibitor, exhibits antiviral activity following a single oral dose in HIV-1-infected patients. 12th Conf Retroviruses Opportunistic Infect (Feb 22-25, Boston) 2005, Abst 159.
44. Martin, D.E., Gailbraith, H., Schettler, J., Ellis, C., Doto, J. Lack of a PK/PD interaction between PA-457 and atazanavir (ATV) in healthy volunteers. 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst A-377.